421 related articles for article (PubMed ID: 23742285)
21. Chronic idiopathic urticaria: treatment with omalizumab.
Naaman S; Sussman G
Skin Therapy Lett; 2014; 19(6):1-4. PubMed ID: 25807072
[TBL] [Abstract][Full Text] [Related]
22. Effects of omalizumab in a patient with three types of chronic urticaria.
Vieira Dos Santos R; Locks Bidese B; Rabello de Souza J; Maurer M
Br J Dermatol; 2014 Feb; 170(2):469-71. PubMed ID: 24102388
[No Abstract] [Full Text] [Related]
23. [Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases].
Díez LS; Tamayo LM; Cardona R
Biomedica; 2013; 33(4):503-12. PubMed ID: 24652205
[TBL] [Abstract][Full Text] [Related]
24. Effect of omalizumab on patients with chronic urticaria.
Spector SL; Tan RA
Ann Allergy Asthma Immunol; 2007 Aug; 99(2):190-3. PubMed ID: 17718108
[TBL] [Abstract][Full Text] [Related]
25. Omalizumab (Xolair) for the treatment of chronic idiopathic urticarial.
Scheinfeld N
Skinmed; 2014; 12(5):294-7. PubMed ID: 25632648
[No Abstract] [Full Text] [Related]
26. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142
[TBL] [Abstract][Full Text] [Related]
27. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.
Kim DH; Park KY; Kim BJ; Kim MN; Mun SK
Clin Exp Dermatol; 2013 Jul; 38(5):496-500. PubMed ID: 23083013
[TBL] [Abstract][Full Text] [Related]
28. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
Lang DM
Ann Allergy Asthma Immunol; 2014 Apr; 112(4):276-9. PubMed ID: 24589165
[No Abstract] [Full Text] [Related]
29. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
[TBL] [Abstract][Full Text] [Related]
30. Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?
Tontini C; Marinangeli L; Cognigni M; Bilò MB; Antonicelli L
Ann Allergy Asthma Immunol; 2015 Aug; 115(2):147-8. PubMed ID: 26048249
[No Abstract] [Full Text] [Related]
31. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
[No Abstract] [Full Text] [Related]
32. Therapy of chronic urticaria: a simple, modern approach.
Kaplan AP
Ann Allergy Asthma Immunol; 2014 May; 112(5):419-25. PubMed ID: 24656924
[TBL] [Abstract][Full Text] [Related]
33. Omalizumab in children.
Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
[TBL] [Abstract][Full Text] [Related]
34. Biologic agents and the therapy of chronic spontaneous urticaria.
Kaplan AP; Popov TA
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):347-53. PubMed ID: 24936849
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
36. Anti-IgE--emerging opportunities for Omalizumab.
Babu KS; Polosa R; Morjaria JB
Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
[TBL] [Abstract][Full Text] [Related]
37. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
38. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
[TBL] [Abstract][Full Text] [Related]
39. Response to: 'Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria: a critical appraisal'.
Rosén K; Maurer M; Hsieh H; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
Br J Dermatol; 2014 Jul; 171(1):15-6. PubMed ID: 25066290
[No Abstract] [Full Text] [Related]
40. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
